Quigg RJ - Search Results

1

Complement-dependent apoptosis and inflammatory gene changes in murine lupus cerebritis.

Alexander JJ, Jacob A, Bao L, Macdonald RL, Quigg RJ. Alexander JJ, et al. Among authors: quigg rj. J Immunol. 2005 Dec 15;175(12):8312-9. doi: 10.4049/jimmunol.175.12.8312. J Immunol. 2005. PMID: 16339572

2

Alteration in kidney glucose and amino acids are implicated in renal pathology in MRL/lpr mice.

Alexander JJ, Zwingmann C, Jacob A, Quigg R. Alexander JJ, et al. Biochim Biophys Acta. 2007 Oct;1772(10):1143-9. doi: 10.1016/j.bbadis.2007.07.002. Epub 2007 Aug 22. Biochim Biophys Acta. 2007. PMID: 17942282 Free article.

3

Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice.

Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, Alexander JJ, Anderson RK, Culhane K, Holers VM, Quigg RJ. Bao L, et al. Among authors: quigg rj. J Immunol. 2002 Apr 1;168(7):3601-7. doi: 10.4049/jimmunol.168.7.3601. J Immunol. 2002. PMID: 11907125

4

Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation.

Bao L, Zhou J, Holers VM, Quigg RJ. Bao L, et al. Among authors: quigg rj. J Am Soc Nephrol. 2003 Oct;14(10):2516-25. doi: 10.1097/01.asn.0000089831.96794.0b. J Am Soc Nephrol. 2003. PMID: 14514729

5

Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis.

Alexander JJ, Bao L, Jacob A, Kraus DM, Holers VM, Quigg RJ. Alexander JJ, et al. Among authors: quigg rj. Biochim Biophys Acta. 2003 Nov 20;1639(3):169-76. doi: 10.1016/j.bbadis.2003.09.005. Biochim Biophys Acta. 2003. PMID: 14636948 Free article.

6

Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis.

Bao L, Osawe I, Haas M, Quigg RJ. Bao L, et al. Among authors: quigg rj. J Immunol. 2005 Aug 1;175(3):1947-55. doi: 10.4049/jimmunol.175.3.1947. J Immunol. 2005. PMID: 16034139

7

C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist.

Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ. Bao L, et al. Among authors: quigg rj. Eur J Immunol. 2005 Aug;35(8):2496-506. doi: 10.1002/eji.200526327. Eur J Immunol. 2005. PMID: 16052609 Free article.

8

The simple design of complement factor H: Looks can be deceiving.

Alexander JJ, Quigg RJ. Alexander JJ, et al. Among authors: quigg rj. Mol Immunol. 2007 Jan;44(1-3):123-32. doi: 10.1016/j.molimm.2006.07.287. Epub 2006 Aug 17. Mol Immunol. 2007. PMID: 16919753 Review.

9

Complement in lupus nephritis: the good, the bad, and the unknown.

Bao L, Quigg RJ. Bao L, et al. Among authors: quigg rj. Semin Nephrol. 2007 Jan;27(1):69-80. doi: 10.1016/j.semnephrol.2006.09.009. Semin Nephrol. 2007. PMID: 17336690 Review.

10

Absence of functional alternative complement pathway alleviates lupus cerebritis.

Alexander JJ, Jacob A, Vezina P, Sekine H, Gilkeson GS, Quigg RJ. Alexander JJ, et al. Among authors: quigg rj. Eur J Immunol. 2007 Jun;37(6):1691-701. doi: 10.1002/eji.200636638. Eur J Immunol. 2007. PMID: 17523212 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

175 results

Search Page

Filters